The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Russell's Viper

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Russell's Viper

 

High impact information on Russell's Viper

  • In the absence of heparin, SAP (5-125 micrograms/ml) had no effect on clot times generated by Activated Thrombofax Reagent, brain thromboplastin, Russell's Viper Venom or thrombin when assessed in normal citrated plasma [6].
  • Anti-beta2GPI mAbs directed against the third domain (Cof-20 and Cof-22) and fourth domain (Cof-21, EY1C8, and EY2C9) of beta2GPI inhibited the thrombin generation induced by Russell's viper venom in diluted plasma and that induced by the prothrombinase complex reconstituted with purified clotting factors [7].
  • In the present study we have prepared activated Factor IX by incubating human Factor IX with calcium and Russell's viper venom covalently bound to agarose [8].
  • Membrane phospholipid organization was determined by using bee venom phospholipase-A2 and indirectly by measuring clotting time on recalcification of normal human platelet-poor plasma in the presence of Russell's viper venom [9].
  • Russell's viper venom, a control Factor X-activating serine protease, was not inhibited by either 0.1 mM HgCl2 or 1 mM iodoacetamide [10].
 

Chemical compound and disease context of Russell's Viper

 

Biological context of Russell's Viper

 

Anatomical context of Russell's Viper

 

Associations of Russell's Viper with chemical compounds

  • Factor IX is also converted to Factor IXaalpha by a protease from Russell's viper venom [22].
  • Triggering was attempted by injection of Russell's viper venom (RVV), which is a proteolytic procoagulant, and histamine [23].
  • The activation peptide cleaved near the amino terminus by a protease from Russell's viper venom differs in both size and sequence from those of other serine proteases [24].
  • Factor X-activating glycoprotein of Russell's viper venom. Polypeptide composition and characterization of the carbohydrate moieties [25].
  • Both factor Va, activated by thrombin or by the factor V activator from Russell's viper venom, and the isolated fragments, D (Mr = 105,000), C1 (Mr = 150,000), and F1F2 (Mr = 72,000), were studied [26].
 

Gene context of Russell's Viper

  • The Factor V (Leiden) test: evaluation of an assay based on dilute Russell Viper Venom Time for the detection of the Factor V Leiden mutation [27].
  • A functional assay for protein S is not readily available for clinical use; however, we have developed a functional protein S assay based on the prolongation of Russell viper venom (RVV) plasma clotting time by protein C activated by PROTAC [28].
  • EMPs were measured using positivity for monoclonal antibodies (mAbs) CD31 and CD51, and their procoagulant activity was assessed using a Russell viper venom assay [29].
  • The sequence of TSV-PA exhibits a high degree of sequence identity with other snake venom proteases: 66% with the protein C activator from Agkistrodon contortrix contortrix venom, 63% with batroxobin, and 60% with the factor V activator from Russell's viper venom [30].
  • Following purification to homogeneity and activation by the factor X activator from Russell viper venom, the mutants were characterized with respect to their ability to assemble into the prothrombinase complex to activate prothrombin and interact with target plasma fXa inhibitors, tissue factor pathway inhibitor (TFPI) and antithrombin [31].
 

Analytical, diagnostic and therapeutic context of Russell's Viper

  • We examined not only the levels of antibodies to prothrombin and anti-beta2-GP I (both IgG and IgM isotypes) using an ELISA system, but also LA activity detected using both diluted Russell's viper venom time (dRVVT) and STACLOT LA test in 124 patients with SLE [32].
  • Recombinant mouse factor X was expressed in human embryonic kidney cells and secreted into cell culture supernatant as zymogen, which could be converted to catalytically active factor Xa by Russell's viper venom [33].

References

  1. Aortic medial necrosis with or without thrombosis in rabbits treated with Russell's viper venom and angiotensin II. Nakamura, M., Abe, S., Kinukawa, N. Atherosclerosis (1997) [Pubmed]
  2. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. Somers, E., Magder, L.S., Petri, M. J. Rheumatol. (2002) [Pubmed]
  3. The kidney in tropical snakebite. Sitprija, V., Boonpucknavig, V. Clin. Nephrol. (1977) [Pubmed]
  4. Risk factors for pulmonary emboli after total hip or knee arthroplasty. Mont, M.A., Jones, L.C., Rajadhyaksha, A.D., Shuler, M.S., Hungerford, D.S., Sieve-Smith, L., Wang, P., Cordista, A.G., Glueck, C.J. Clin. Orthop. Relat. Res. (2004) [Pubmed]
  5. Heparin therapy in Russell's viper bite victims with disseminated intravascular coagulation: a controlled trial. Tin Na Swe, n.u.l.l., Myint Lwin, n.u.l.l., Khin Ei Han, n.u.l.l., Tin Tun, n.u.l.l., Tun, P. Southeast Asian J. Trop. Med. Public Health (1992) [Pubmed]
  6. Modulation of fibrin clot formation by human serum amyloid P component (SAP) and heparin. Ku, C.S., Fiedel, B.A. J. Exp. Med. (1983) [Pubmed]
  7. Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids. Takeya, H., Mori, T., Gabazza, E.C., Kuroda, K., Deguchi, H., Matsuura, E., Ichikawa, K., Koike, T., Suzuki, K. J. Clin. Invest. (1997) [Pubmed]
  8. Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill. Griffith, M.J., Breitkreutz, L., Trapp, H., Briet, E., Noyes, C.M., Lundblad, R.L., Roberts, H.R. J. Clin. Invest. (1985) [Pubmed]
  9. In vivo externalization of phosphatidylserine and phosphatidylethanolamine in the membrane bilayer and hypercoagulability by the lipid peroxidation of erythrocytes in rats. Jain, S.K. J. Clin. Invest. (1985) [Pubmed]
  10. A factor X-activating cysteine protease from malignant tissue. Gordon, S.G., Cross, B.A. J. Clin. Invest. (1981) [Pubmed]
  11. A protein C pathway (PCP) screening test for the detection of APC resistance and protein C or S deficiencies. Haas, F.J., van Sterkenburg-Kamp, B.M., Scheepers, H.A. Semin. Thromb. Hemost. (1998) [Pubmed]
  12. Antiphospholipid antibodies in pediatric patients with prolonged activated partial thromboplastin time during infection. Frauenknecht, K., Lackner, K., von Landenberg, P. Immunobiology (2005) [Pubmed]
  13. Recombinant thromboplastin inhibition assay for the detection of lupus anticoagulant. Zanon, E., Saracino, M.A., Simioni, P., Scarano, L., Girolami, B., Girolami, A. Clinical and laboratory haematology. (1995) [Pubmed]
  14. Coagulation factor X activating enzyme from Russell's viper venom (RVV-X). A novel metalloproteinase with disintegrin (platelet aggregation inhibitor)-like and C-type lectin-like domains. Takeya, H., Nishida, S., Miyata, T., Kawada, S., Saisaka, Y., Morita, T., Iwanaga, S. J. Biol. Chem. (1992) [Pubmed]
  15. Aprotinin, cardiac surgery, and factor V Leiden. Sweeney, J.D., Blair, A.J., Dupuis, M.P., King, T.C., Moulton, A.L. Transfusion (1997) [Pubmed]
  16. Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Rai, R.S., Regan, L., Clifford, K., Pickering, W., Dave, M., Mackie, I., McNally, T., Cohen, H. Hum. Reprod. (1995) [Pubmed]
  17. Acute effect of Russell's viper (Vipera russelli siamensis) venom on renal hemodynamics and autoregulation of blood flow in dogs. Sanguanrungsirikul, S., Chomdej, B., Suwanprasert, K., Wattanavaha, P. Toxicon (1989) [Pubmed]
  18. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays. Favaloro, E.J., Mirochnik, O., McDonald, D. Br. J. Biomed. Sci. (1999) [Pubmed]
  19. Low concentrations of indomethacin inhibit phospholipase A2 of rabbit polymorphonuclear leukocytes. Kaplan, L., Weiss, J., Elsbach, P. Proc. Natl. Acad. Sci. U.S.A. (1978) [Pubmed]
  20. The formation of a thrombin-like material (TLM) following stimulation of leukocytes. Nishizawa, E.E., Della-Coletta, A.A. Thromb. Res. (1984) [Pubmed]
  21. Comparative thermometric coagulation studies of plasmas from normal outbred Swiss Webster mice and persons. Tsang, V.C., Wyatt, C.R., Damian, R.T. Am. J. Vet. Res. (1979) [Pubmed]
  22. Activation of human factor IX (Christmas factor). Di Scipio, R.G., Kurachi, K., Davie, E.W. J. Clin. Invest. (1978) [Pubmed]
  23. Triggering of plaque disruption and arterial thrombosis in an atherosclerotic rabbit model. Abela, G.S., Picon, P.D., Friedl, S.E., Gebara, O.C., Miyamoto, A., Federman, M., Tofler, G.H., Muller, J.E. Circulation (1995) [Pubmed]
  24. Bovine factor X1 (Stuart factor): amino-acid sequence of heavey chain. Titani, K., Fujikawa, K., Enfield, D.L., Ericsson, L.H., Walsh, K.A., Neurath, H. Proc. Natl. Acad. Sci. U.S.A. (1975) [Pubmed]
  25. Factor X-activating glycoprotein of Russell's viper venom. Polypeptide composition and characterization of the carbohydrate moieties. Gowda, D.C., Jackson, C.M., Hensley, P., Davidson, E.A. J. Biol. Chem. (1994) [Pubmed]
  26. Bovine coagulation factor V visualized with electron microscopy. Ultrastructure of the isolated activated forms and of the activation fragments. Dahlbäck, B. J. Biol. Chem. (1986) [Pubmed]
  27. The Factor V (Leiden) test: evaluation of an assay based on dilute Russell Viper Venom Time for the detection of the Factor V Leiden mutation. Quehenberger, P., Handler, S., Mannhalter, C., Kyrle, P.A., Speiser, W. Thromb. Res. (1999) [Pubmed]
  28. A simple functional protein S assay using PROTAC. Han, P., Pradham, M. Clinical and laboratory haematology. (1990) [Pubmed]
  29. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease. Jimenez, J.J., Jy, W., Mauro, L.M., Horstman, L.L., Ahn, Y.S. Br. J. Haematol. (2001) [Pubmed]
  30. A novel plasminogen activator from snake venom. Purification, characterization, and molecular cloning. Zhang, Y., Wisner, A., Xiong, Y., Bon, C. J. Biol. Chem. (1995) [Pubmed]
  31. Role of basic residues of the autolysis loop in the catalytic function of factor Xa. Manithody, C., Yang, L., Rezaie, A.R. Biochemistry (2002) [Pubmed]
  32. Anti-prothrombin antibodies combined with lupus anti-coagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Nojima, J., Kuratsune, H., Suehisa, E., Futsukaichi, Y., Yamanishi, H., Machii, T., Kitani, T., Iwatani, Y., Kanakura, Y. Br. J. Haematol. (2001) [Pubmed]
  33. Cloning and recombinant expression of mouse coagulation factor X. Heidtmann, H.H., Kontermann, R.E. Thromb. Res. (1998) [Pubmed]
 
WikiGenes - Universities